ERBB2 and cancer: Subsequent receptor phosphorylation triggers signal transduction to downstream candidates, promoting cancer cell proliferation.5 Various HER2-targeted cancer drugs, including trastuzumab (rst-line therapy), neratinib, pertuzumab, and other second/third-line therapy, are available for treating this subtype of patients.3,4,6,7